Vydura vs Sumatriptan

Migraines are a complex neurological condition affecting around 1 in 7 people. More than just a headache, they often require specific treatments, which exceed the capability of simple painkillers like paracetamol.

The gold standard is sumatriptan, which works by affecting blood vessels and pain signals in the brain. Those who cannot take sumatriptan, may benefit from Vydura, a newer treatment which is also licensed as a preventative.

Between the new vs old migraine treatment, which one is right for you? Read on to learn more about each treatment and take control of your migraines today.

How Each Medication Works

Sumatriptan belongs to the triptan family and works by tightening blood vessels which widen during a migraine attack. Additionally, it reduces pain signal transmission, helping to reduce pain and other associated symptoms.

Its effect on blood vessels make it unsuitable for anyone who has underlying cardiovascular problems.

It usually takes about 30-60 mins for sumatriptan tablets to start working with optimal effect occurring after 2 hours. Sumatriptan is also available as a nasal spray which starts working within 15 minutes.

As a low cost, generic medication, sumatriptan is the most common migraine treatment prescribed on the NHS. It is also available from Quick Meds following a short clinical assessment.

Vydura, containing the drug rimegepant, is known as a CGRP receptor antagonist. CGRP is released by nerves during a migraine and transmits pain signals. By blocking this, rimegepant can stop pain transmission and other associated symptoms.

As opposed to triptans, rimegepant can be taken every other day as a preventative. It also suits individuals who have cardiovascular history and cannot take triptans.

Vydura stays in the body much longer than sumatriptan (half life of 11 hours compared to 2 hours for sumatriptan). Because of this, it reduces the risk of pain returning the same day.

If you are taking sumatriptan more than twice a week, you may be at risk of medicine overuse headache. Switching to Vydura can break this cycle whilst still providing relief.

The MHRA approved Vydura in 2022, with NICE following in 2023 for NHS use. As a newer treatment, rimegepant is still under patent and currently only available as the brand Vydura. It is not yet widely prescribed through the NHS but remains available to eligible patients privately.

Head-to-Head Comparison Table

If you need to stop a migraine immediately, sumatriptan is the drug of choice, especially the nasal spray.

If you suffer from frequent attacks, Vydura is superior as it can treat the current attack, reduce the risk of the pain recurring and can be used as a preventative. Additionally, if you have been told to avoid triptans, due to heart health, Vydura is the preferred treatment.

Clinical Evidence: What the Trials Show

Comparing the clinical evidence for the two treatments reveals:

• Sumatriptan offers greater effectiveness for a single attack whilst

• Vydura offers a safer option, fewer side effects and prevention of the attack in the first place.

Clinical trials assessing the effectiveness of sumatriptan tablets found:

• 51% of patients taking 50mg tablets were pain free after 2 hours

• 66% of patients taking 100mg were pain free after 2 hours

• Compared to 19.6% with placebo

Rimegepant offers more moderate relief, with trials showing between 19-21% of participants were pain free after 2 hours, compared to 11% with placebo. However, it excels at symptom management with 35% of patients becoming free from their most bothersome symptoms at 2 hours post dose.

Whilst trials indicate sumatriptan offers greater effectiveness, the ‘best ’choice depends on your medical history and how often you experience migraines.

• Cardiovascular health - triptans cannot be taken by those with heart problems as they tighten blood vessels. Vydura is a suitable alternative.

• Frequency and prevention - Vydura is the preferred choice for those who suffer from frequent attacks. It stays in the body longer, does not carry a risk of medicine overuse headache and can be used as prevention.

• Side effect profile - Though more effective, 43% of patients taking sumatriptan reported adverse events. Vydura is preferred for those who have had to stop triptans due to side effects.

Side Effect Profiles Compared

The deciding factor usually comes down to the side effects. Whilst effective, sumatriptan side effects can cause distress whereas Vydura has a side-effect profile almost identical to placebo.

Common side effects of Sumatriptan, sometimes termed ‘triptan sensations’ include:

• Chest and throat sensations - tightness/pressure in the chest and throat

• Paraesthesia - tingling/numbness in fingers and toes

• Vasomotor reactions - Flushing and dizziness

• Fatigue or weakness

• Flushing, hot/cold sensations

Who should not take sumatriptan (contraindications):

As it constricts blood vessels, sumatriptan cannot be taken by anyone with:

• Uncontrolled high blood pressure

• History of stroke or TIA

• Peripheral vascular disease

• Ischemic heart disease - including a history of heart attack or prinzmetal’s angina

• Specific migraine types, such as hemiplegic or basilar migraines.

The most common side effect of Vydura is nausea. Aside from this and allergic reactions, no other side effects were noted in clinical trials.

Vydura should be avoided:

• In patients with severe hepatic (liver) impairment

• In patients with end-stage kidney disease

Vydura should be avoided in pregnancy as a precautionary measure - there is limited data to support its safe use.

Cost, Availability & How to Get Each in the UK

Whilst both treatments are licensed, the pathway to receive them on the NHS differs:

• Sumatriptan - widely available. Usually the first choice drug where traditional painkillers have not helped

• Vydura - As per NICE, is only prescribed when at least 2 triptans have been tried and did not work or were not tolerated.

If you do not meet the strict NHS criteria or wish to avoid long waiting lists, both treatments are available through private consultation at Quick Meds. To place an order:

• Online questionnaire - complete a short form which asks about your symptoms and medical history

• Choose your treatment - Select your preferred treatment and complete payment

• Clinical review - A UK-registered pharmacist will review your order and approve if clinically appropriate

• Delivery - Once approved, orders are packaged discreetly and sent straight to you, using tracked delivery methods.

The cost-per-dose varies greatly between the two treatments and, as of March 2026:

Prices above include private prescription fees but exclude postage and packaging fees.

For those who have no history of heart disease and are after an affordable, fast-acting treatment, Sumatriptan is the best option to manage infrequent migraines.

If you cannot tolerate triptans or you experience side effects, Vydura may be the better option for you. Whilst cost-per-dose is higher, the reduction in migraine free days can outweigh the price for chronic sufferers.

When to Switch or Combine

Many patients start their migraine treatment with sumatriptan, but if this does not lead to desired results, you should switch to Vydura, especially if:

• Treatment failure - you have used sumatriptan for at least three attacks and have failed to achieve pain relief.

• Worsening side effects - the ‘triptan sensations’ are too uncomfortable to tolerate.

• 10 day rule - if you are taking sumatriptan for more than 10 days each month - risking medication overuse headache.

• Cardiovascular changes - if you develop high blood pressure or heart disease.

Some patients may consider combining treatments. Clinical trials have confirmed it is safe to do so and should be done by:

• Using Vydura as base treatment - taking everyday as a preventative treatment.

• Taking Sumatriptan as a rescue treatment - for when a breakthrough migraine occurs.

The path you take in your migraine journey should always be supervised by a healthcare professional. Ensure to get in touch to stay on top of your symptoms.